Defense Health Agency Contracting Activity - DHACA
· Federal agency
DoD Peer Reviewed Orthopaedic, Clinical Translational Research Award
Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Joint Theatre Trauma Reg...
94
match
Deadline1377 days agoLocationAlabamaTypegrantLevelFederalClosedposted Apr 8, 2022
✦ AI Summary
Who can apply: Federal-level applicants (see eligibility for details).
Funding amount: total funding pool ~$6,000,000.
Next deadline: September 13, 2022.
Issued by: Defense Health Agency Contracting Activity - DHACA.
The “key facts” mode pulls structured fields directly from the official source posting (amount, deadline, eligibility tags). The AI mode adds a short plain-English narrative on top, generated from the same source. Always verify with the agency before applying.
AI-generated. Always verify with the official source.
Deadline
1377 days ago
Sep 13, 2022
Total pool
$6M
About this opportunity
Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Joint Theatre Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat ( during training, leisure activities, resultant from old injuries, etc.) present one of the greatest threats to the readiness of our Service Members and military. Early rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness. The PRORP is interested in supporting research that will have an impact on the lives of all individuals that have sustained a major musculoskeletal injury.The PRORP CTRA is intended to support high-impact and/or new/emerging clinical research that may or may not be ready for a full-scale randomized controlled clinical trial. Projects should demonstrate potential to impact the standard of care, both immediate and long-term, as well as contribute to evidence-based guidelines for the evaluation and care of military, Veterans and all patients with orthopaedic injuries.• One goal of the FY22 PRORP CTRA is to translate current and emerging techniques and interventions into the clinical space to better serve military patients. The health, functional abilities, and quality of life of individuals who have sustained an orthopaedic injury should be considered.• Another goal is to identify the most effective prevention options available to support critical decision-making for caregivers, and policymakers.The FY22 PRORP CTRA differs from the FY22 PRORP Clinical Trial Award (CTA) in that the CTRA allows for clinical research projects that may or may not include a clinical trial, whereas the CTA is restricted to clinical trials only.Applications to the FY22 PRORP Clinical Translational Research Award mechanism must support clinical research and may not be used for animal research. Animal research is not allowed under this funding opportunity. Investigators seeking support to conduct studies involving animal research should consider applying to the FY22 PRORP Applied Research Award (funding opportunity number W81XWH-22-PRORP-ARA [Applied Research Award]) mechanism, which can be accessed at https://cdmrp.army.mil/funding/.The proposed studies may be interventional and may involve some retrospective data analysis. Note that purely retrospective or database-related research is not allowed under this funding opportunity. Small pilot clinical trials with human subjects are allowable.Key aspects of the PRORP Clinical Translational Research Award Mechanism:• Preliminary data are required: Inclusion of preliminary data relevant to the proposed clinical study is required.• Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical study appropriate to the objectives of the study.• Intervention Availability, as applicable: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate and applicable, for the proposed duration of the study.• Personnel and Environment: The application should demonstrate the study team’s expertise and experience in all aspects of conducting clinical research, including appropriate statistical analysis, knowledge of Food and Drug Administration (FDA) processes (if applicable), and data management.
Read the agency's eligibility checklist before you start — it's almost always shorter than the full NOFO and will tell you in 90 seconds whether to keep going.
Need help getting in touch with the right agency contact?
Create a free account and our specialists will guide you through the application end-to-end.